☆ 4.7 Article

The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation

Keng Hee Peh et al.

Summary: Molecular tumor boards can provide precision treatment recommendations based on genomic profiles, but there are practical barriers to their implementation. In this study, the clinical utility of a precision medicine molecular tumor board (PMMTB) was evaluated, and challenges with its implementation were described. The results show that nonstandard of care (SOC) recommendations from the PMMTB benefited a majority of patients, but there were also barriers such as patient response to current treatment and lack of financial support for treatment.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2023)

Add to Collection

Article Oncology

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report

Matteo Allegretti et al.

Frontiers in Oncology (2023)

Add to Collection

Article Oncology

Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience

Bryan H. Louie et al.

Summary: Personalized combination therapy based on molecular characteristics can be more effective for advanced colorectal cancer. The implementation of a Molecular Tumor Board (MTB) led to improved progression-free survival in patients by matching drugs to individual tumor alterations.

MOLECULAR ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

Gennaro Ciliberto et al.

Summary: Most MTBs are supported through local grants and mostly meet regularly. They adopt virtual or mixed meeting models. The ACC MTB initiative is shaping a virtual MTB network, resembling cost-effective health-care organization models. The overall public awareness of MTB opportunities remains insufficient.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology

Patricia Martin-Romano et al.

Summary: The study aims to investigate the clinical impact of matching targetable genomic alterations in patients with advanced cancer according to the ESCAT scale. The results show a significant association between ESCAT and objective response rates and progression-free survival.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Letter Biochemistry & Molecular Biology

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

Matteo Allegretti et al.

MOLECULAR CANCER (2021)

Add to Collection

Review Oncology

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

Kara L. Larson et al.

Summary: This systematic review evaluated the impact of Molecular Tumor Board (MTB) review on clinical outcomes in cancer patients. 14 studies with 3,328 patients were included, showing improved clinical outcomes with MTB-recommended therapy. More prospective trials and standardization of approach and outcomes are needed for future research.

JCO PRECISION ONCOLOGY (2021)

Add to Collection

Article Oncology

Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience

Michelle F. Green et al.

Summary: Comprehensive genomic profiling is essential in oncology care but can be challenging for oncologists to interpret. The Molecular Registry of Tumors (MRT) and Molecular Tumor Board (MTB) provide a solution by aggregating genomic data and facilitating targeted therapy selection. Through MRT, therapeutic sensitivity, resistance alterations, and potential germline implications can be identified, ultimately improving precision cancer medicine programs.

JCO PRECISION ONCOLOGY (2021)

Add to Collection

Article Oncology

Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer

Bin Huang et al.

Summary: The study found that MTB review is an independent positive predictor of overall survival for non-small-cell lung cancer patients. Lack of MTB review and living in the Appalachian region were both associated with poorer survival outcomes. MTBs may help reduce health disparities for disadvantaged populations by improving survival rates.

JCO PRECISION ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Shumei Kato et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Oncology

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

F. Mosele et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

Jason K. Sicklick et al.

NATURE MEDICINE (2019)

Add to Collection

Review Oncology

Molecular screening programs in different countries: what we learned and perspectives

Edith Borcoman et al.

CURRENT OPINION IN ONCOLOGY (2019)

Add to Collection

Article Oncology

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

J. Mateo et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie

Clemence Basse et al.

ESMO OPEN (2018)

Add to Collection

Article Oncology

Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer

Christian Rolfo et al.

ESMO OPEN (2018)

Add to Collection

Article Oncology

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery

Alan H. Bryce et al.

ONCOTARGET (2017)

Add to Collection

© Peeref 2019-2024. All rights reserved.